Shilpa Medicare Unit Acquires 30.4% Stake in Gate2Brain for €7 Million
Published on: June 8, 2026, 3:45 p.m. | Source: scanx.trade
Shilpa Medicare's subsidiary Shilpa Biocare Pvt Ltd has acquired a 30.4% stake in Barcelona-based Gate2Brain, S.L. for €7 million, comprising €0.5 million cash, €5.5 million equity for services, and €1 million in development funding. The partnership focuses on G2B-002, a first-in-class brain cancer therapy targeting DIPG and pediatric glioblastoma, which holds Orphan Drug Designation from both the US FDA and EMA, with first-in-human trials aimed for FY28.
